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Sir,
We would like to thank the authors for their comments on our
recent review article ‘evolving treatment strategies for myeloma’.
Although very rare, the occasional patient may present with a
pyrexia of unknown origin (PUO), arising presumably from
cytokines released by the myeloma plasma cells. While we agree
this is possible, it should not be the first conclusion as the
immunosuppressed myeloma patient is at great risk of infection.
These patients represent a difficult diagnostic challenge and need
to be screened for active infection and treated with antibiotics
where appropriate. The only clear proof that the temperature is
related to the myeloma is that it will resolve when antimyeloma
treatment is initiated. However, it is important not to delay the
initiation of treatment, which may be detrimental to the patient.
Therefore, we totally agree that once active infection had been
ruled out in a newly diagnosed patient with a PUO, chemotherapy
should be initiated promptly.
The antitumour role of bisphosphonates in myeloma is
intriguing especially with the highly potent third-generation
compounds such as zoledronic acid, which are now in routine
use. To date, their antimyeloma effect has only been shown in cell
lines and mouse models. The apoptotic action of sodium
clodronate is clearly different from that of zoledronic acid.
Clodronate is metabolised to a number of ATP analogues, which
are resistant to hydrolysis and therefore accumulate within the cell
resulting in the inhibition of important metabolic enzymes, such as
phosphatases and pyrophosphatases, whereas zoledronic acid
inhibits the mevalonate pathway leading to an inhibition of the
prenylation of small GTPases important in cell signalling, such as
RAS. While these and other effects such as inhibition of gd T cells
are clearly demonstratable in vitro, their relevance in vivo is less
clear. Dose levels in this setting are lower, and the drugs rapidly
leave the circulation and become fixed in the bone; thus, it has to
be postulated that bisphosphonates are concentrated in proximity
to osteoclasts and can reach doses that are able to kill them. The
relevance of this mechanism to myeloma plasma cells rather than
osteoclasts is less certain. However, what is clear is that the direct
inhibition of bone resorption and the resulting change in the
pattern of cytokines produced can inhibit positive feedback loops
important in maintaining survival of the myeloma clone.
Available data from numerous clinical trials only support the
effect of bisphosphonates in inhibiting bone resorption and
reducing skeletal-related events, and we believe that no conclusion
regarding their in vivo antimyeloma effect can be drawn at present.
We agree in view of the dramatic effects on skeletal-related events
that all patients should receive a bisphosphonate; however,
whether this should be a first- or third-generation derivative is
unclear. We eagerly await the results of the current large Medical
Research Council randomised phase III trial, which compares oral
sodium clodronate with intravenous zoledronic acid in order to
determine whether there is any differential antimyeloma effect in
patients.
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